NeuBase Therapeutics, Inc. Business Combination, Consideration Transferred
NeuBase Therapeutics, Inc. had Business Combination, Consideration Transferred of $12.66 million as of 2019-07-12, per its 10-K filed 2020-12-23.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2020-12-23
- 2019-07-12: Business Combination, Consideration Transferred $12.66M.
- 2014-05-30: Business Combination, Consideration Transferred 0 month $18.56M; Business Combination, Consideration Transferred 0 month as first filed $20.04M.
| Period end | Business Combination, Consideration Transferred | Business Combination, Consideration Transferred 0 month | Business Combination, Consideration Transferred 0 month as first filed |
|---|---|---|---|
| 2019-07-12 | $12.66M 10-K · filed 2020-12-23 | ||
| 2014-05-30 | $18.56M 10-K · filed 2016-12-22 | $20.04M 10-Q · filed 2014-08-18 |